FDA Approves Lirafugratinib for Bile Duct Cancer with 46% Response Rate
The FDA cleared lirafugratinib for previously treated FGFR2-positive cholangiocarcinoma, with nearly half of patients responding and median survival topping 22 months.
Summary
The FDA has approved lirafugratinib (Lyrfigtu), a new oral drug targeting the FGFR2 protein, for adults with previously treated bile duct cancer carrying FGFR2 gene fusions or rearrangements. About 8,000 Americans are diagnosed with this cancer each year, and treatment options have historically been limited. In the phase I/II ReFocus trial of 116 patients, nearly half responded to the drug, disease was controlled in 96.5% of cases, and median overall survival reached 22.8 months. Unlike earlier FGFR inhibitors, lirafugratinib binds irreversibly and selectively to FGFR2, which helps overcome resistance mutations. Experts highlight the importance of molecular testing at diagnosis to match patients with targeted therapies most likely to benefit them.
Detailed Summary
Bile duct cancer, or cholangiocarcinoma, is a rare but aggressive malignancy with roughly 8,000 new U.S. diagnoses annually. For patients whose disease has progressed after initial treatment, meaningful options have been scarce — making this FDA approval a notable advance in precision oncology.
The newly approved drug, lirafugratinib (Lyrfigtu), is an oral inhibitor that selectively and irreversibly binds to FGFR2, a growth-factor receptor frequently mutated or rearranged in cholangiocarcinoma. Its covalent-binding mechanism distinguishes it from earlier pan-FGFR inhibitors, allowing it to overcome many resistance mutations that tend to develop with prior-generation drugs while reducing off-target toxicity.
Approval rested primarily on results from the phase I/II ReFocus trial involving 116 patients with FGFR2-positive, previously treated cholangiocarcinoma who had not received a prior FGFR inhibitor. The objective response rate was 46%, and disease control was achieved in an impressive 96.5% of participants. Median progression-free survival was 11.3 months, with 49.2% of patients progression-free at 12 months. Median overall survival reached 22.8 months, with 74.6% alive at one year — results considered durable for this patient population.
The most common serious side effects were palmar-plantar erythrodysesthesia (hand-foot syndrome) in 32.8% of patients and stomatitis in 12.1%. FDA prescribing information flags additional warnings for ocular toxicity, hyperphosphatemia, soft-tissue mineralization, and fetal toxicity.
Clinically, the approval reinforces a broader shift toward molecular profiling at the time of cancer diagnosis. Identifying FGFR2 fusions early allows patients to be directed toward targeted therapies rather than generic chemotherapy. Lirafugratinib is expected to become commercially available in the U.S. before the end of the year, offering a much-needed new option for a cancer with historically poor outcomes.
Key Findings
- Lirafugratinib achieved a 46% objective response rate in previously treated FGFR2-positive bile duct cancer patients.
- Disease control rate was 96.5%, with median overall survival of 22.8 months and 74.6% alive at one year.
- Its irreversible, selective FGFR2 binding helps overcome resistance mutations seen with earlier FGFR inhibitors.
- Most common serious adverse event was hand-foot syndrome (32.8%), with stomatitis in 12.1% of patients.
- Molecular testing at diagnosis is critical to identifying FGFR2 fusions and matching patients to targeted therapy.
Methodology
This is a news report summarizing an FDA approval announcement and associated phase I/II clinical trial (ReFocus). The source, MedPage Today, is a credible medical news outlet; findings are grounded in peer-reviewed trial data from 116 patients with FGFR2-positive cholangiocarcinoma. As a non-randomized phase I/II study without a control arm, efficacy estimates should be interpreted with that context in mind.
Study Limitations
The ReFocus trial was a single-arm phase I/II study without a randomized comparator, limiting causal conclusions about survival benefit relative to existing therapies. The patient population had no prior FGFR inhibitor exposure, so generalizability to broader real-world populations may be limited. Long-term safety and outcomes data beyond the trial follow-up period are not yet available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: